Oncolytics says interim phase 1 data shows Reolysin/radiation treatment well tolerated

By Lisa Kerner

Erie, Pa., April 4 - Oncolytics Biotech Inc. said interim results of its phase 1 combination Reolysin/radiation clinical trial indicate that the combination of intratumoural Reolysin and radiation was well tolerated and that both local clinical responses and early indications of systemic effects were observed.

The company presented the interim results at the American Association for Cancer Research annual meeting in Washington, D.C.

Oncolytics said the phase 1 open label study is evaluating the feasibility, safety and antitumor effects of intratumoral administration of Reolysin in combination with localized radiation therapy in patients with advanced cancers, using two different radiation dosages and schedules.

The primary objective is to determine the maximum tolerated dose and the safety profile of Reolysin administered intratumorally, with a secondary objective of antitumor activity.

"Indications of activity when combining Reolysin with what is generally considered to be a palliative dose of radiation are certainly encouraging," president and chief executive officer Brad Thompson said in a company news release.

"On the strength of this data, we are currently designing a phase 2 combination Reolysin/radiation trial, at this radiation dosage, for inclusion in our overall phase 2 clinical program. That trial is expected to begin following the completion of the ongoing phase 1 trial."

Oncolytics is a Calgary, Alta.-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.